| [Non-alcoholic fatty liver disease of liver stagnation and spleen deficiency pattern treated with acupoint embedding therapy: a randomized controlled trial] 2016 · western medication group · People with non-alcoholic fatty liver disease of the liver stagnation and spleen deficiency pattern | 684 mg | 26 weeks | 90 |
| First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses 2014 · 0.8 g LT-02 group · Patients with mesalazine-refractory ulcerative colitis; age and sex not specified | 800 mg | 12 weeks | 41 |
| First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses 2014 · 1.6 g LT-02 group · Patients with mesalazine-refractory ulcerative colitis; age and sex not specified | 1.6 g | 12 weeks | 40 |
| First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses 2014 · 3.2 g LT-02 group · Patients with mesalazine-refractory ulcerative colitis; age and sex not specified | 3.2 g | 12 weeks | 35 |
| Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis 2005 · phosphatidylcholine-treated group · Adults with chronic active, non-steroid-dependent ulcerative colitis and a clinical activity index of at least 4 | 6 g | 90 days | 30 |
| Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial 2007 · phosphatidylcholine recipients · Adults with chronic steroid-refractory ulcerative colitis and high clinical and endoscopic disease activity | 2 g | 12 weeks | 30 |
| Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study 2010 · 0.5 g daily group · Patients with chronic-active ulcerative pancolitis who were not receiving steroids | 500 mg | 12 weeks | 10 |
| Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study 2010 · 1 g daily group · Patients with chronic-active ulcerative pancolitis who were not receiving steroids | 1 g | 12 weeks | 10 |
| Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study 2010 · 3 g daily group · Patients with chronic-active ulcerative pancolitis who were not receiving steroids | 3 g | 12 weeks | 10 |
| Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study 2010 · 4 g daily group · Patients with chronic-active ulcerative pancolitis who were not receiving steroids | 4 g | 12 weeks | 10 |
| Effect of phosphatidylcholine on explicit memory 1993 · 10 g phosphatidylcholine · College students; age and sex not specified | 10 g | 1 day | — |
| Effect of phosphatidylcholine on explicit memory 1993 · 25 g phosphatidylcholine · College students; age and sex not specified | 25 g | 1 day | — |
| Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk 2013 · Choline group · Healthy pregnant women recruited in the second trimester and their infants; maternal age and infant sex range not stated | 3.7 g | 244 days | 46 |
| Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients 1994 · PPC group · Adults with non-insulin-dependent diabetes and secondary hyperlipidemia | 2.7 g | 60 days | — |
| Choline supplementation for preterm infants: metabolism of four Deuterium-labeled choline compounds 2023 · D9-POPC · Preterm infants born at 28 0/7–32 0/7 weeks’ gestation, both sexes, receiving enteral feeds | 2.7 mg/kg | 1 day | 8 |
| Differential metabolism of choline supplements in adult volunteers 2022 · Egg-phosphatidylcholine (egg-PC) · Healthy adult men aged 18 years or older | 4.02 g | 1 day | 6 |
| Different choline supplement metabolism in adults using deuterium labelling 2023 · D9-POPC · Healthy adult men aged 26–65 | 18.6 mg/kg | 1 day | 6 |
| Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group 1998 · PPC group · Patients with chronic hepatitis B or C | 1.8 g | 48 weeks | 92 |
| A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury 2017 · polyene phosphatidylcholine group · Adults aged 24–66, any sex, with statin-induced liver injury and elevated ALT | 1.37 g | 4 weeks | 78 |
| Vitaphospholip® (water-soluble phosphatidylcholine) in the treatment of combined hyperlipidemia: a randomized, placebo-controlled clinical trial 2025 · Vitaphospholip® group · Patients with combined hyperlipidemia | 1 g | 12 weeks | 39 |
| [The effect of polyene phosphatidylcholine administration on lipid metabolism and glucose tolerance in patients with hyperlipoproteinemia IIB] 1995 · polyene phosphatidylcholine (PPC) · Patients with hyperlipoproteinemia type IIB and hypoalfacholesterolemia | 2.7 g | 90 days | 30 |
| Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men 2005 · phosphatidylcholine · Healthy men with mildly elevated plasma homocysteine concentrations | 2.6 g | 2 weeks | 26 |
| Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial 2021 · phosphatidylcholine capsules · Healthy men and women aged 18 years or older with normal renal function | 840 mg | 4 weeks | — |
| Pharmacokinetics of soy-derived lysophosphatidylcholine compared with that of glycerophosphocholine: a randomized controlled trial 2024 · LPC supplementation · Healthy men; age not specified | 480 mg | 1 day | — |
| Effects of dietary fish oil and soy phosphatidylcholine on neutrophil fatty acid composition, superoxide release, and adhesion 1998 · group 2, soybean phosphatidylcholine · healthy volunteers matched for sex and age | 25 g | 2 weeks | — |
| Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans 2005 · Study 4 phosphatidylcholine group · Healthy men aged 50–71 years with plasma homocysteine below 26 μmol/L | 34 g | 2 weeks | 26 |
| Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial 2020 · Phytosomal curcumin · Adults aged 18–70 years with overweight (BMI 25–30 kg/m²) and suboptimal fasting plasma glucose (100–125 mg/dL) | 480 mg | 8 weeks | 40 |